Biotech funds topped the list of best-performing funds in November, while gold funds suffered during the month as investors rotated back into risk assets, according to Willis Owen.
Pictet Biotech was the best-performing fund last month, delivering a return of 13.65% based on FE Fundinfo data from 31 October to 30 November, followed by Polar Capital Biotechnology, which generated a return of 12.44% and Candriam Equities L Biotechnology, which returned 12.2% during the month. Adrian Lowcock, head of personal investing at Willis Owen, said: "This appears to be a combination of 'a rising tide lifts all boats' and a growing belief that no matter who wins the 2020 Presidential election the impact of Medicare for all is not going to have as big [an] effect on the biotech ...
To continue reading this article...
Join Investment Week for free
Signup and gain exclusive members-only insights - all free of charge!
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
